Mark Lamotte

Validation of the IMS CORE Diabetes Model

Phil McEwan, V. Foos, James L. Palmer et al. · Value in Health · 2014 · 240 citations

Medicine, Internal Medicine, Clinical Decision Support +16

Incidence, Medical Resource Utilisation and Costs of Hyperuricemia and Tumour Lysis Syndrome in Patients with Acute Leukaemia and Non-Hodgkin's Lymphoma in Four European Countries

L Annemans, K Moeremans, Mark Lamotte et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2002 · 153 citations

Medicine, Oncology, Pharmacoeconomics +17

Cost-Effectiveness of Early Irbesartan Treatment Versus Control (Standard Antihypertensive Medications Excluding ACE Inhibitors, Other Angiotensin-2 Receptor Antagonists, and Dihydropyridine Calcium Channel Blockers) or Late Irbesartan Treatment in Patients With Type 2 Diabetes, Hypertension, and Renal Disease

Andrew Palmer, Lieven Annemans, Stéphane Roze et al. · Diabetes Care · 2004 · 93 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacotherapy +16

Patient and caregiver productivity loss and indirect costs associated with cardiovascular events in Europe

Kornelia Kotseva, Laetitia Gerlier, Eduard Sidelnikov et al. · European Journal of Preventive Cardiology · 2019 · 93 citations

Medicine, Cardiology, Internal Medicine +17

Computer Modeling of Diabetes and Its Transparency: A Report on the Eighth Mount Hood Challenge

Andrew Palmer, Lei Si, Michelle Tew et al. · Value in Health · 2018 · 78 citations · Full text

Medicine, Endocrinology, Health Informatics +14